Ahmed M Elkhanany

6PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology diagnostics (incl. biosensors)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 24, 2026
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

|Jun 23, 2023
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.

Sibel Blau, Julio Antonio Peguero, Halle C F Moore

|May 13, 2023
Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma.

Brooke B Bartow, Gene P Siegal, Ceren Yalniz

|Feb 03, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany

|Nov 05, 2022
Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.

Neelima Vidula, Andrew Lipman, Shumei Kato

|Jan 04, 2021
Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion.

Song Yao, Ting-Yuan David Cheng, Ahmed Elkhanany

Pageof 1

Frequent Collaborators

1 joint publications

Song Yao

1 joint publications

Ting-Yuan David Cheng

1 joint publications

Angela Omilian

1 joint publications

Scott I Abrams